Pioneering biomarker technologies for Cancer therapies. Our biomarkers are used to identify the right patient, the right drug and the right dose. Using our biomarker tests provides more effective treatment for patients and economic savings for the healthcare system. Our colorectal cancer tests are validated using thousands of patient samples and are set to transform the current treatment pathway. Oxford developed prognostic assay fo.

The Oxford Biobank investigations focus on research into common diseases like diabetes, obesity and cardiovascular disease. If you have visited the Oxford BioBank and would like to comment on your experiences, please visit our Feedback Page. This website uses cookies to improve your experience.

We are excited to announce new partnerships with Four Seasons Fuel. And the Oxford Charcoal Company.

Chromosome conformation signatures response to methotrexate in early rheumatoid arthritis. OBD presents latest ALS biomarker data at the 6th World CNS Summit. Annual Report and Accounts for the year ended 30 Sep 2017 published. Oxford BioDynamics announces grant of Indian patent for its proprietary technology platform, EpiSwitch . We are a biotechnology company with a proprietary biomarker discovery platform, EpiSwitch.

Oxford Biolabs is committed to employing safe and efficient therapies for the management of hair loss, particularly when caused by Androgenetic Alopecia. The research is ongoing to continuously improve and update the current TRX2 formula as well as create supporting products to further improve the effectiveness of TRX2. Oxford Biolabs is committed to employing safe and efficient therapies for the management of hair loss, particularly when caused by Androgeneti.